Neogenomics (NEO) EBIAT (2016 - 2025)
Historic EBIAT for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to -$27.1 million.
- Neogenomics' EBIAT fell 5327.98% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.5 million, marking a year-over-year decrease of 4598.09%. This contributed to the annual value of -$78.7 million for FY2024, which is 1050.61% up from last year.
- Per Neogenomics' latest filing, its EBIAT stood at -$27.1 million for Q3 2025, which was down 5327.98% from -$45.1 million recorded in Q2 2025.
- Neogenomics' EBIAT's 5-year high stood at $75.9 million during Q2 2021, with a 5-year trough of -$49.4 million in Q1 2022.
- For the 5-year period, Neogenomics' EBIAT averaged around -$22.0 million, with its median value being -$24.3 million (2023).
- Examining YoY changes over the last 5 years, Neogenomics' EBIAT showed a top increase of 121185.52% in 2021 and a maximum decrease of 89577.63% in 2021.
- Over the past 5 years, Neogenomics' EBIAT (Quarter) stood at -$41.8 million in 2021, then soared by 45.67% to -$22.7 million in 2022, then surged by 36.85% to -$14.3 million in 2023, then dropped by 6.97% to -$15.3 million in 2024, then crashed by 77.04% to -$27.1 million in 2025.
- Its EBIAT was -$27.1 million in Q3 2025, compared to -$45.1 million in Q2 2025 and -$25.9 million in Q1 2025.